Table 4.
Short‐form survey‐36 scores assessing the quality of life
| Mean (SD) | Mean difference (95% CI)a | p‐value (between group)* | ||||
|---|---|---|---|---|---|---|
| Domains | Group | Baseline (n = 25) | Week 4 (n = 25) | Week 8 (n = 25) | ||
| Physical functioning | Ashwagandha | 56.4 (15.51) | 64.2 (16.87) | 74.0 (17.85) | 7.86 (88.85 to −73.13) | 0.25 |
| Placebo | 59.8 (11.31) | 71.20 (25.15) | 69.0 (16.13) | |||
| Energy/fatigue | Ashwagandha | 46.8 (10.29) | 51.8 (10.19) | 55.4 (8.65) | −2 (13.15 to −17.15) | 0.94 |
| Placebo | 45.4 (8.52) | 54.0 (8.41) | 56.0 (11.81) | |||
| Emotional wellbeing | Ashwagandha | 50.72 (6.99) | 57.92 (8.72) | 64.0 (9.52) | 1.36 (13.04 to −10.32) | 0.95 |
| Placebo | 52.24 (5.89) | 60.8 (8.64) | 64.16 (12.08) | |||
| Social functioning | Ashwagandha | 51.0 (6.16) | 54.00 (7.83) | 58.5 (7.83) | −4 (4.64 to −12.64) | 0.56 |
| Placebo | 48.5 (5.49) | 55.5 (8.89) | 60.0 (10.20) | |||
| Pain | Ashwagandha | 46.8 (5.32) | 55.7 (11.62) | 63.3 (13.82) | −0.1 (15.07 to 15.27) | 0.71 |
| Placebo | 45.2 (5.04) | 56.5 (12.09) | 61.8 (15.18) | |||
| General health | Ashwagandha | 54.2 (10.47) | 55.0 (12.41) | 60.2 (13.34) | −3.6 (18.21 to −25.41) | 0.72 |
| Placebo | 51.6 (11.87) | 54.4 (11.93) | 61.2 (11.48) | |||
*p‐value was obtained using independent two‐sample t‐test for mean within the group (two‐tailed, α = 0.05).
a
Mean difference was obtained subtracting Week 8 and baseline differences in the ashwagandha and placebo groups.